Designed for biotechnology and pharmaceutical laboratories, the well filter plates process volumes up to 7 mL for simple plate-to-plate transfers and a time-saving, cost-cutting filtration platform.
Pall Laboratory’s AcroPrep high-volume 24-well filter plates, launched in late January 2021, allows for laboratories to work within a 24-well format from cell growth, harvest, and biomolecule isolation to final analysis while offering a high throughput, less work steps and sample losses, and reduced processing times.
Designed for biotechnology and pharmaceutical laboratories, the well filter plates process volumes up to 7 mL for simple plate-to-plate transfers and a time-saving, cost-cutting filtration platform. The plates feature a polypropylene construction which promotes low protein binding to minimize sample loss. Plates are available in several pore sizes, including Omega PES membrane in all molecular weight cut-offs, and a polyethylene/polypropylene membrane.
"Pall's introduction of the industry's broadest line of 24-well filter plates provides researchers with the ultimate convenience of a true one-stop resource for their filtration workflow needs," said Lori Euler, Pall's product manager, Molecular, in a Jan. 26, 2021 company press release. "The new plates permit seamless operations throughout 24-well plate manual and automated processes, creating higher efficiencies and greater productivity.”
Source: Pall
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.